Department of Veterans Affairs
Network Contracting Office 16 - HOUSTON
In Support of the Michael E. DeBakey VA Medical Center (MEDVAMC)
REQUEST FOR INFORMATION
36C25619Q0854
BACKGROUND:
MEDVAMC has a requirement for the following Genetic Testing:
Statement of Work
GENERAL: The Michael E. DeBakey VA Medical Center (MEDVAMC) is pursuing a contract with a base year and four (4) one-year options and an emergency six-month extension at the end of the last option year for genetic testing.
SCOPE: The MEDVAMC is requesting referral genetic testing for the following list of Test Names and their respective test codes:
Test Code
Test Name
1300
BLUEPRINT PANEL
1390
TOTAL BLUEPRINT PANEL
1399
WHOLE EXOME SEQUENCING - PROBAND - REFLEX AFTER BLUEPRINT
1500
WHOLE EXOME SEQUENCING - PROBAND
1530
WHOLE EXOME SEQUENCING - PROBAND + CMA
1531
WHOLE EXOME SEQUENCING - PROBAND + COMP MTDNA ANALYSIS
1532
WHOLE EXOME SEQUENCING - TRIO + COMP MTDNA ANLYS
1533
WHOLE EXOME SEQUENCING - TRIO + COMP MTDNA ANLYS - CRITICAL
1580
CUSTOM FAMILY SEQUENCING - GENE 1
1600
WHOLE EXOME SEQUENCING - TRIO
1622
WHOLE EXOME SEQUENCING - TRIO - PRENATAL
1722
WHOLE EXOME SEQUENCING - TRIO - CRITICAL
1800
WHOLE GENOME SEQUENCING - TRIO
2000
MITOMET PLUS ACGH ANALYSIS
2001
OLIGONUCLEOTIDE ACGH ANALYSIS TARGETED ANALYSIS
2085
DUAL GENOME PANEL BY NGS
2090
LOW BONE MASS PANEL BY NGS
2140
PEO PANEL BY NGS
2554
ATP7B - SEQ AND DEL/DUP ANALYSIS
3069
POLG - SEQ AND DEL/DUP ANALYSIS
3200
MITO RESP CHAIN ENZYME ANALYSIS - SKELETAL MUSCLE
3284
LPIN1 - SEQ AND DEL/DUP ANALYSIS
3404
GAA - SEQ AND DEL/DUP ANALYSIS
3600
HEREDITARY PARAGANGLIOMA PHEOCHROMOCYTOMA SYNDROMES PANEL
3660
RET - SEQUENCE ANALYSIS
3665
MEN1 - SEQUENCE ANALYSIS
3740
FH - SEQUENCE ANALYSIS
4100
AMINO ACID ANALYSIS - PLASMA
4200
URINE ORGANIC ACID
4300
PLASMA CARNITINE AND ACYLCARNITINE
4569
HEXA HEXB - ENZYME ANALYSIS - SERUM
6011
GLA - SEQ AND DEL/DUP ANALYSIS
6031
FXN - FRIEDREICH ATAXIA REPEAT EXPANSION ANALYSIS
6034
HTT - HUNTINGTON DISEASE REPEAT EXPANSION ANALYSIS
6035
HFE - MUTATION PANEL
6037
AR - KENNEDY DISEASEE REPEAT EXPANSION ANALYSIS
6041
DMPK - MYOTONIC DYSTROPHY TYPE 1 REPEAT EXPANSION ANALYSIS
6062
THROMBOPHILIA MUTATION PANEL
6085
DMD - FAMILIAL MUTATION/VARIANT ANALYSIS
6087
APC - SEQUENCE ANALYSIS
Test Code
Test Name
6089
APC - FAMILIAL MUTATION/VARIANT ANALYSIS
6095
MLH1 - SEQUENCE ANALYSIS
6096
MSH2 - SEQUENCE ANALYSIS
6097
MSH6 - SEQUENCE ANALYSIS
6098
HNPCC MSI AND IHC SCREENING
6103
MUTYH - FAMILIAL MUTATION/VARIANT ANALYSIS
6104
MUTYH - MUTATION PANEL
6118
TP53 - SEQUENCE ANALYSIS
6119
TP53 - FAMILIAL MUTATION/VARIANT ANALYSIS
6120
MUTYH - SEQUENCE ANALYSIS
6121
RECQL4 - SEQUENCE ANALYSIS
6122
RECQL4 - FAMILIAL MUTATION/VARIANT ANALYSIS
6142
MLH1 - FAMILIAL MUTATION/VARIANT ANALYSIS
6143
MSH2 - FAMILIAL MUTATION/VARIANT ANALYSIS
6144
MSH6 - FAMILIAL MUTATION/VARIANT ANALYSIS
6376
CFTR - SEQ AND DEL/DUP ANALYSIS
6380
ARSA - SEQUENCE ANALYSIS
6415
GALC - SEQUENCE ANALYSIS
6505
PTEN - SEQUENCE ANALYSIS
6510
PTEN - FAMILIAL MUTATION/VARIANT ANALYSIS
6520
RUNX1 - SEQUENCE ANALYSIS
6525
RUNX1 - FAMILIAL MUTATION/VARIANT ANALYSIS
6573
FMR1 - CGG REPEAT EXPANSION ANALYSIS
6585
COL5A1 - SEQUENCE ANALYSIS
6590
COL5A2 - SEQUENCE ANALYSIS
6640
PMS2 - SEQUENCE ANALYSIS
6641
PMS2 - FAMILIAL MUTATION/VARIANT ANALYSIS
6705
MLH1 - SEQ AND DEL/DUP ANALYSIS
6706
MLH1 - DEL/DUP ANALYSIS
6710
MSH2 - SEQ AND DEL/DUP ANALYSIS
6711
MSH2 - DEL/DUP ANALYSIS
6715
MSH6 - SEQ AND DEL/DUP ANALYSIS
6716
MSH6 - DEL/DUP ANALYSIS
6720
APC - SEQ AND DEL/DUP ANALYSIS
6721
APC - DEL/DUP ANALYSIS
6740
LDLR - SEQ AND DEL/DUP ANALYSIS
6765
VHL - SEQUENCE ANALYSIS
6766
VHL - FAMILIAL MUTATION/VARIANT ANALYSIS
6770
VHL - SEQ AND DEL/DUP ANALYSIS
6775
VHL - DEL/DUP ANALYSIS
6785
PTEN - DEL/DUP ANALYSIS
6790
PTEN - SEQ AND DEL/DUP ANALYSIS
6795
PMS2 - DEL/DUP ANALYSIS
6820
TP53 - DEL/DUP ANALYSIS
6821
TP53 - SEQ AND DEL/DUP ANALYSIS
6888
EPCAM - DELETION ANALYSIS
6890
PMS2 - SEQ AND DEL/DUP ANALYSIS
7521
COL2A1 - SEQ AND DEL/DUP ANALYSIS
8025
ONCOLOGY FISH - ERBB2 (HER2/NEU)
8030
ALK GENE REARRANGEMENT BY FISH ANALYSIS
8031
ONCOLOGY FISH - RET REARRANGEMENT
8035
EGFR FISH ANALYSIS
8050
ONCOLOGY CHROMOSOME ANALYSIS - SOLID TUMOR
8055
1P/19Q CO-DELETION BY FISH - FFPE
8060
1P/19Q CO-DELETION BY FISH - FRESH TISSUE
8065
DXZ1/DYZ3 FISH FOR SEX MISMATCHED BMT
8075
ONCOLOGY FISH - SS18
Test Code
Test Name
8080
ONCOLOGY FISH - TCF3/PBX1 FISH for ALL
8085
ClariFind FISH
8095
ONCOLOGY FISH - MET
8300
ONCOLOGY CHROMOSOME ANALYSIS
8385
ONCOLOGY FISH - GAIN 8 CHROMOSOME
8405
CUSTOM FISH
8410
ANEUPLOIDY FISH
8425
RAPID FISH - ANEUVYSION T13 T18 T21 X Y
8426
RAPID FISH ANALYSIS SEX CHROMOSOME X/SRY
8430
FISH ANALYSIS - LANGER GIEDION SYNDROME PANEL EXT1 AND TRPS1
8435
FISH ANALYSIS - MULTIPLE EXOSTOSES PANEL EXT1 AND EXT2
8440
FISH ANALYSIS - DIGEORGE/VELOCARDIOFACIAL SYND 22Q AND 10P
8450
FISH ANALYSIS - WAGR SYNDROME WT1 AND PAX6
8455
FISH ANALYSIS - WILMS WT1 TUMOR
8456
FISH ANALYSIS - 1P36 DELETION SYNDROME
8457
FISH ANALYSIS - ADRENAL HYPOPLASIA CONGENITA
8458
FISH ANALYSIS - ALAGILLE SYNDROME JAG1 RELATED
8459
FISH ANALYSIS - ANGELMAN SYNDROME
8460
FISH ANALYSIS - BECKWITH-WIEDEMANN SYNDROME
8462
FISH ANALYSIS - CHARCOT MARIE TOOTH CMT1A DISEASE
8464
FISH ANALYSIS - CRI DU CHAT SYNDROME
8465
FISH ANALYSIS - DIGEORGE SYNDROME II 10P ONLY
8466
FISH ANALYSIS - GLYCEROL KINASE DEFICIENCY
8467
FISH ANALYSIS - HNPP
8468
FISH ANALYSIS - LIS1 ASSC LSSNCPLY/SBCRTCL BAND HETEROTOPIA
8469
FISH ANALYSIS - KALLMAN SYNDROME TYPE I
8470
FISH-MICROPHTHALMIA WITH LINEAR SKIN LESIONS MLS/MIDAS
8471
FISH ANALYSIS - MILLER-DIEKER SYNDROME
8472
FISH ANALYSIS - MULTIPLE EXOSTOSES 1 EXT1
8473
FISH-MULTIPLE EXOSTOSES 2 / POTOCKI-SHAFFER EXT2 AND ALX4
8474
FISH ANALYSIS - NEUROFIBROMATOSIS 1
8476
FISH ANALYSIS - PRADER-WILLI SYNDROME
8477
FISH ANALYSIS - RUBINSTEIN-TAYBI SYNDROME
8478
FISH ANALYSIS - SMITH-MAGENIS SYNDROME
8479
FISH ANALYSIS - SOTOS SYNDROME
8480
FISH ANALYSIS - SRY ANALYSIS
8482
FISH ANALYSIS - TRICHORHINOPHALANGEAL SYNDROME TYPE I
8483
FISH ANALYSIS - WILLIAMS SYNDROME
8484
FISH ANALYSIS - WOLF-HIRSCHORN SYNDROME
8485
FISH ANALYSIS - X-LINKED ICHTHYOSIS/STS DEFICIENCY
8486
FISH ANALYSIS - DIGEORGE/VELOCARDIOFACIAL SYND TYPE I 22Q
8500
CHROMOSOME ANALYSIS - PRENATAL - AMNIO WITH AFP
8520
CHROMOSOME ANALYSIS - PRENATAL - AFP ACHE FH
8530
CHROMOSOME ANALYSIS - PRENATAL - AMNIOTIC FLUID
8540
CHROMOSOME ANALYSIS - PRENATAL - AMNIO WITH ACHE
8600
CHROMOSOME ANALYSIS - BLOOD
8639
CHROMOSOMAL MICROARRAY ANALYSIS - TISSUE
8655
CHROMOSOMAL MICROARRAY ANALYSIS - HR
8656
TARGETED CMA - PRENATAL DIAGNOSIS - AMNIOTIC FLUID
8657
TARGETED CMA - PRENATAL DIAGNOSIS - CVS
8665
CHROMOSOMAL MICROARRAY ANALYSIS - HR SNP SCREEN
8670
EXPANDED CHROMOSOMAL MICROARRAY ANALYSIS - PRENATAL - AMNIO
8671
EXPANDED CHROMOSOMAL MICROARRAY ANALYSIS - PRENATAL - CVS
8672
CMA TARGETED AND LIMITED KARYOTYPE - PRENATAL - CVS
8673
CMA TARGETED AND LIMITED KARYOTYPE - PRENATAL - AMNIO
8675
CMA EXPANDED AND LIMITED KARYOTYPE - PRENATAL - AMNIO
8676
CMA EXPANDED AND LIMITED KARYOTYPE - PRENATAL - CVS
Test Code
Test Name
8700
CHROMOSOME ANALYSIS - PRENATAL - CVS
8710
ONCOLOGY FISH - DELETION 5 MDS
8715
ONCOLOGY FISH - DELETION 7 MDS
8720
ONCOLOGY FISH - DELETION 20Q12 MDS
8725
ONCOLOGY FISH - ETO/AML1 T 8 21 AML
8730
ONCOLOGY FISH - CHIC2 DELETED 4Q HYPEREOSINOPHILIC SYNDROME
8735
ONCOLOGY FISH - PML/RARA T 15 17 AML
8740
ONCOLOGY FISH - CBFB INV 16 AML
8745
ONCOLOGY FISH - MLL 11Q24
8750
ONCOLOGY FISH - BCR/ABL t 9 22 CML/ALL/AML
8755
ONCOLOGY FISH - TEL/AMLI T 12 21 ALL
8760
ONCOLOGY FISH - MYC TRANSLOCATION
8765
ONCOLOGY FISH - IGH/BCL2 T 14 18 FOLLICULAR LYMPHOMA
8770
ONCOLOGY FISH - IGH/CCND1 T 14 11 MANTLE CELL LYMPHOMA
8775
ONCOLOGY FISH - BCL6
8780
ONCOLOGY FISH - IGH
8781
ONCOLOGY FISH - ROS1
8785
BCL2 rearrangement
8786
MALT1 lymphoma
8787
non-small cell lung cancer FISH
8788
Oncology FISH Analysis p53
8789
Aggressive high-grade B-cell Lymphoma FISH panel
8840
TISSUE CULTURE AND FREEZE BACK
8972
BCR-ABL1 minor (p190) Quantitative
8975
PD-L1 22C3 IHC for NSCLC by immunohistochemistry with interpretation. Pembrolizumab (KEYTRUDA)
8976
PD-L1 28-8 pharmDx IHC w/ interpretation. Nivolumab
8977
PD-L1 22C3 IHC with combined positive score (CPS) interpretation. Pembrolizumab (KEYTRUDA)
9003
BRAF V600E MUTATION DETECTION IN HAIRY CELL LEUKEMIA
9005
NPM1 MUTATION BY PCR AND FRAGMENT ANALYSIS
9010
JAK2 GENE, V617F MUTATION, QUALITATIVE
9015
JAK2 EXON 12 MUTATION ANALYSIS BY PCR
9016
CALR (CALRETICULIN) EXON 9 MUTATION ANALYSIS BY PCR
9020
MPL CODON 515 MUT DETECT BY PYROSEQUENCING, QUANT
9030
EGFR MUTATION DETECTION BY PYROSEQUENCING
9045
FLT3 - MUTATION ANALYSIS
9055
TP53 SOMATIC MUTATION, PROGNOSTIC
9057
TP53 - TARGETED MUTATION ANALYSIS - GERMLINE
9060
IGHV MUTATION ANALYSIS BY SEQUENCING
9065
BCR-ABL1, MAJOR (P210), QUANTITATIVE
9070
BCR-ABL1, QUALITATIVE WITH REFLEX TO BCR-ABL1 QUANTITATIVE
9080
PML-RARA TRANSLOCATION, T(15;17) BY RT-PCR, QUANTITATIVE
9086
CEBPA Mutation Detection
9103
KIT MUTATIONS, MELANOMA
9104
GASTROINTESTINAL STROMAL TUMOR MUTATION
9105
KIT MUTATIONS IN AML BY FRAGMENT ANALYSIS AND SEQUENCING
9128
KRAS MUTATION DETECTION
9150
MICROSATELLITE INSTABILITY MSI, HNPCC/LYNCH SYNDROME, BY PCR
9202
B-CELL CLONALITY SCREENING (IGH AND IGK) BY PCR
9217
COMPREHENSIVE T-CELL CLONALITY ANALYSIS
9305
BCR-ABL1 MUT ANALYS TYROSINE KINASE INHIBITOR RESISTANCE NGS
9505
CANCER CHROMOSOMAL MICROARRAY ANALYSIS - 180K CGH/SNP ARRAY
9515
CYTOSCAN HD SNP ARRAY - TUMOR
9705
SOLID TUMOR MUTATION PANEL
20004
HEREDITARY CANCER PANEL COMPREHENSIVE
20010
ClariFind Comprehensive DNA Panel
20640
MTHFR - GENE SEQUENCING BY NGS
Test Code
Test Name
22304
HEREDITARY BRAIN CNS PNS CANCER PANEL
22335
PHOX2B - GENE SEQUENCING BY NGS
22350
BRCA1/BRCA2 - SEQ AND DEL/DUP ANALYSIS
22404
HEREDITARY BREAST/OVARIAN/ENDOMETRIAL CANCER PANEL
22504
HEREDITARY RENAL CANCER PANEL BY NGS
22505
CDKN1C - GENE SEQUENCING BY NGS
22510
FLCN - GENE SEQUENCING BY NGS
22604
HEREDITARY ENDOCRINE CANCER PANEL BY NGS
22704
HEREDITARY LEUKEMIA/LYMPHOMA PANEL BY NGS
22804
HEREDITARY COLORECTAL/GASTROINTESTINAL CANCER PANEL
22820
ENG - GENE SEQUENCING BY NGS
22904
HEREDITARY MELANOMA PANEL BY NGS
23000
HEREDITARY BREAST CANCER PANEL HIGH RISK
23104
HEREDITARY PARAGANGLIOMA/PHEOCHROMOCYTOMA PANEL
23204
HEREDITARY COLORECTAL CANCER PANEL HIGH RISK
23304
HEREDITARY PANCREATIC CANCER PANEL BY NGS
23404
HEREDITARY PROSTATE CANCER PANEL BY NGS
24000
COMMON HEREDITARY CANCER PANEL (27 genes)
29271
NDP - FAMILIAL MUTATION/VARIANT ANALYSIS
60101
GENEAWARE COMPLETE FEMALE V2
60106
GENEAWARE COMPLETE MALE V2
60201
GENEAWARE ASHKENAZI JEWISH FEMALE V2
60206
GENEAWARE ASHKENAZI JEWISH MALE V2
60301
GENEAWARE ACMG/ACOG FEMALE V2
60306
GENEAWARE ACMG/ACOG MALE V2
60401
GENEAWARE BASIC FEMALE V2
60406
GENEAWARE BASIC MALE V2
The contractor shall provide and ensure safe, secure, and careful handling of the patient samples and the reporting of results in accordance with established guidelines from the Department of Veterans Affairs Handbook 6500, the College of American Pathologists (CAP), the Joint Commission on Accreditation of Health Care Organizations (JCAHO), guidelines established by VA Laboratory Service or as required to follow the Health Insurance Portability and Accountability Act of 1996 (HIPAA) during transportation.
PERIOD OF PERFORMANCE:
Base Period: Oct. 1, 2019 to Sept. 30, 2020
Option Year 1: Oct. 1, 2020 to Sept. 30, 2021
Option Year 2: Oct. 1, 2021 to Sept. 30, 2022
Option Year 3: Oct. 1, 2022 to Sept. 30, 2023
Option Year 4: Oct. 1, 2023 to Sept. 30, 2024
GOVERNMENT S RESPONSIBILITY: They send out laboratory personnel at the MEDVAMC will affix a label containing the patient s full name and full social security number to the specimen s container in order to ensure integrity of the information, place the specimen (that is being sent for processing) in a sealed tamper evident container and prepare it for pickup. The MEDVAMC will then call the contractor to arrange immediate pickup and direct delivery to the Genetics testing Lab.
REQUESTED RESPONSES:
The intent of this Request for Information is to establish sources to define the procurement strategy (e.g set-aside, sole source, unrestricted) for a solicitation that VA intends to post soon. Interested contractors are requested to respond in accordance with the following:
Please respond to this RFI if you can provide the exact brand name products listed in the table in the background section above. In the response please cite your business size status.
If you have an existing GSA or VA, Federal Supply Schedule contract, please include the contract details in your response.
DISTRIBUTORS: You must provide proof that you are an authorized distributor. VA does not accept grey market items.
Please respond to this RFI if you can provide supplies that may be determined EQUIVALENT to the products listed in the table in the background section above. Please provide details on the proposed EQUIVALENT products such as Manufacturer Name, Part Number, and Description.
If you have an existing GSA or VA, Federal Supply Schedule contract, please include the contract details in your response.
DISTRIBUTORS: You must provide proof that you are an authorized distributor. VA does not accept grey market items.
Please note that VA is particularly interested in determining the availability of Small Business Manufacturers. If your company is a small business manufacturer of potentially equivalent items, please respond to this RFI.
Vendors are requested to submit estimated market research pricing with their responses. The estimated pricing will be considered when determining the procurement strategy for the future solicitation. (e.g. if CO determines that capable small businesses cannot provide fair and reasonable pricing, then the solicitation will not be set-aside).
Please note that if no responses to this notice are received, from either authorized distributors of the cited brand name nor from manufacturers marketing a potentially equivalent brand, then this action will be sole sourced to the manufacturer cited in the Background section above.
CONTACT INFORMATION AND RESPONSE DUE DATE:
Please email all responses to
[email protected]. Please respond to this RFI no later than May 21, 2019.
DISCLAIMER: This RFI is issued solely for informational and planning purposes and does not constitute a solicitation. Responses to this notice are not offers and cannot be accepted by the Department of Veterans Affairs to form a binding contract. Respondents are solely responsible for all expenses associated with responding to this RFI.
Bid Protests Not Available